A Pilot Test of the Relaxation Response Resiliency Program (3RP) in Spanish Speaking World Trade Center Survivors With Post Traumatic Stress Disorder (PTSD)

October 16, 2017 updated by: NYU Langone Health
The objective of this protocol is to test the feasibility and acceptability of the Relaxation Response Resiliency Program (3RP), a psychotherapy treatment providing a variety of mind body skills and interventions to decrease medical and mental health symptoms and build resilience, in Spanish-speaking World Trade Center (WTC) survivors, and to examine its clinical effectiveness to reduce Post Traumatic Stress Disorder (PTSD), depression, anxiety, and lower respiratory symptoms (LRS) and improve psychosocial functioning.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10016
        • New York University School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • score > or = 44 on the PTSD Checklist PCL, considered the broad definition of PTSD syndrome71
  • report at least one LRS symptoms (i.e., shortness of breath, wheezing, dyspnea or cough).
  • Spanish Speaking

Exclusion Criteria:

  • regular practice of eliciting relaxation response (i.e., meditation, yoga) in the past 6 months,
  • serious unmanaged mental illness including bipolar disorder, psychosis, and active substance misuse disorders;
  • inability to participate in consecutive sessions over 3-month period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Relaxation Response Resiliency Program (3RP)
Other Names:
  • Relaxation Response Resiliency Program

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Structured Clinical Interview (SCID-NP) for Diagnostic and Statistical Manual DSM-IV
Time Frame: 1 Month
State-of-the-art instrument for obtaining psychiatric diagnoses.
1 Month
Symptom Severity using PTSD Checklist
Time Frame: 1 Month
Symptoms will be assessed with the PTSD Checklist (PCL), a 17-item self-report measure of current (past month) PTSD symptoms based on the DSM-IV criteria. It is a widely-used and validated measure of PTSD symptom severity.
1 Month
Assessment of Anxiety Symptoms using Generalized Anxiety Disorder Scale (GAD-7)
Time Frame: 1 Month
1 Month
Measure of Functional Impairment using the Range of Impaired Functioning Tool (RIFT)
Time Frame: 1 Month
widely-used instrument that taps the domains of work, household duties, interpersonal relationships, recreation, and subjective satisfaction with life. Each domain is rated on a five-point scale from very good to very poor. The total score is the sum of the different domains.
1 Month
Assessment of Mindful attention using Mindful Attention Awareness Scale (MAAS)
Time Frame: 1 Month
The MAAS is a 15-item questionnaire on which respondents indicate, on a 6 point Likert-type scale (1 = almost always to 6 = almost never), their level of awareness and attention to present events and experiences.
1 Month
Health Promoting Behaviors will be assessed with the Health Promoting Lifestyles Profile-II (HPLP-II)
Time Frame: 1 Month
he HPLP-II is a 52 item self-report inventory of health behaviors and has been used in previous mind-body treatment studies
1 Month
Measure of treatment expectancy using the Treatment Credibility/Expectancy Questionnaire.
Time Frame: 1 Month
The 6-item Treatment Credibility/Expectancy Questionnaire (CEQ)84 will be used to examine treatment expectancy related to the 3RP.
1 Month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lucia Ferri, MD, New York University Medical School

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2016

Primary Completion (Actual)

October 11, 2017

Study Completion (Actual)

October 11, 2017

Study Registration Dates

First Submitted

March 24, 2016

First Submitted That Met QC Criteria

March 24, 2016

First Posted (Estimate)

March 30, 2016

Study Record Updates

Last Update Posted (Actual)

October 18, 2017

Last Update Submitted That Met QC Criteria

October 16, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Traumatic Stress Disorder (PTSD)

Clinical Trials on 3 RP

Subscribe